Respiratory Syncytial Virus (RSV) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Respiratory Syncytial Virus (RSV) Infections - Drugs In Development, 2022, provides an overview of the Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline landscape.

Respiratory syncytial virus (RSV) infection is a respiratory disease. It infects the lungs and breathing passages. RSV commonly causes bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children less than one year of age. The symptoms of RSV infection include cough, stuffy or runny nose, mild sore throat, earache and fever. Treatment includes proper medication and hygiene practice.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Respiratory Syncytial Virus (RSV) Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Respiratory Syncytial Virus (RSV) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 9, 10, 17, 2, 76, 33 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 14, 12 and 6 molecules, respectively.

Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections (Infectious Disease).
The pipeline guide reviews pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Find and recognize significant and varied types of therapeutics under development for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease).
Classify potential new clients or partners in the target demographic.
Develop tactical initiatives by understanding the focus areas of leading companies.
Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
Formulate corrective measures for pipeline projects by understanding Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Introduction
Report Coverage
Respiratory Syncytial Virus (RSV) Infections - Overview
Respiratory Syncytial Virus (RSV) Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Respiratory Syncytial Virus (RSV) Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Respiratory Syncytial Virus (RSV) Infections - Companies Involved in Therapeutics Development
Respiratory Syncytial Virus (RSV) Infections - Drug Profiles
(human metapneumovirus + human respiratory syncytial virus) (bivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
(human parainfluenza virus [serotype 1] + respiratory syncytial virus) vaccine - Drug Profile
Product Description
Mechanism Of Action
(influenza (virus like particle) + respiratory syncytial virus) vaccine - Drug Profile
Product Description
Mechanism Of Action
(influenza + Coronavirus Disease 2019 (COVID-19) + respiratory syncytial virus) vaccine - Drug Profile
Product Description
Mechanism Of Action
(pertussis + respiratory syncytial virus) vaccine - Drug Profile
Product Description
Mechanism Of Action
ABX-196 - Drug Profile
Product Description
Mechanism Of Action
ADV-110 - Drug Profile
Product Description
Mechanism Of Action
AK-0529 - Drug Profile
Product Description
Mechanism Of Action
AK-0610 - Drug Profile
Product Description
Mechanism Of Action
AK-0611 - Drug Profile
Product Description
Mechanism Of Action
AK-0702 - Drug Profile
Product Description
Mechanism Of Action
ALVR-106 - Drug Profile
Product Description
Mechanism Of Action
Antisense RNAi Oligonucleotide for Respiratory Syncytial Virus (RSV) Infections - Drug Profile
Product Description
Mechanism Of Action
AR-201 - Drug Profile
Product Description
Mechanism Of Action
ASN-500 - Drug Profile
Product Description
Mechanism Of Action
AVG-388 - Drug Profile
Product Description
Mechanism Of Action
AZ-27 - Drug Profile
Product Description
Mechanism Of Action
B-1402 - Drug Profile
Product Description
Mechanism Of Action
BC-0005 - Drug Profile
Product Description
Mechanism Of Action
BC-0335 - Drug Profile
Product Description
Mechanism Of Action
BL-200 - Drug Profile
Product Description
Mechanism Of Action
BLB-201 - Drug Profile
Product Description
Mechanism Of Action
CAL-100 - Drug Profile
Product Description
Mechanism Of Action
CDX-RSV - Drug Profile
Product Description
Mechanism Of Action
clesrovimab - Drug Profile
Product Description
Mechanism Of Action
CR-32T - Drug Profile
Product Description
Mechanism Of Action
CT-02 - Drug Profile
Product Description
Mechanism Of Action
dexamethasone sodium phosphate - Drug Profile
Product Description
Mechanism Of Action
DPX-RSV - Drug Profile
Product Description
Mechanism Of Action
Drugs for Respiratory Syncytial Virus - Drug Profile
Product Description
Mechanism Of Action
Drugs for Viral Infections - Drug Profile
Product Description
Mechanism Of Action
DSCav-1 - Drug Profile
Product Description
Mechanism Of Action
EDP-323 - Drug Profile
Product Description
Mechanism Of Action
EDP-938 - Drug Profile
Product Description
Mechanism Of Action
Fusion Proteins for Coronavirus Disease 2019 (COVID-19) and Respiratory Syncytial Virus (RSV) Infections - Drug Profile
Product Description
Mechanism Of Action
GSK-3844766A - Drug Profile
Product Description
Mechanism Of Action
GSK-3888550A - Drug Profile
Product Description
Mechanism Of Action
HEVS-124 - Drug Profile
Product Description
Mechanism Of Action
IB-004R - Drug Profile
Product Description
Mechanism Of Action
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
infectious disease vaccine - Drug Profile
Product Description
Mechanism Of Action
IVX-121 - Drug Profile
Product Description
Mechanism Of Action
IVXA-12 - Drug Profile
Product Description
Mechanism Of Action
JNJ-64213175 - Drug Profile
Product Description
Mechanism Of Action
JNJ-64400141 - Drug Profile
Product Description
Mechanism Of Action
JNJ-7184 - Drug Profile
Product Description
Mechanism Of Action
JNJ-78991172 - Drug Profile
Product Description
Mechanism Of Action
JNJ-86051823 - Drug Profile
Product Description
Mechanism Of Action
MM-002 - Drug Profile
Product Description
Mechanism Of Action
MM-004 - Drug Profile
Product Description
Mechanism Of Action
molnupiravir - Drug Profile
Product Description
Mechanism Of Action
Monoclonal Antibodies for Respiratory Syncytial Virus (RSV) Infections - Drug Profile
Product Description
Mechanism Of Action
Monoclonal Antibody for Respiratory Syncytial Virus - Drug Profile
Product Description
Mechanism Of Action
Monoclonal Antibody for Respiratory Syncytial Virus Infections - Drug Profile
Product Description
Mechanism Of Action
Monoclonal Antibody to Inhibit RSV F Protein for Respiratory Syncytial Virus Infections - Drug Profile
Product Description
Mechanism Of Action
MPE-8 - Drug Profile
Product Description
Mechanism Of Action
MPE-8 - Drug Profile
Product Description
Mechanism Of Action
MRIRSM-01 - Drug Profile
Product Description
Mechanism Of Action
MRKV-171 - Drug Profile
Product Description
Mechanism Of Action
mRNA-1230 - Drug Profile
Product Description
Mechanism Of Action
mRNA-1345 - Drug Profile
Product Description
Mechanism Of Action
mRNA-1365 - Drug Profile
Product Description
Mechanism Of Action
MV-012968 - Drug Profile
Product Description
Mechanism Of Action
MVA-BN RSV - Drug Profile
Product Description
Mechanism Of Action
Neumifil - Drug Profile
Product Description
Mechanism Of Action
nirsevimab - Drug Profile
Product Description
Mechanism Of Action
nitazoxanide CR - Drug Profile
Product Description
Mechanism Of Action
P-220241 - Drug Profile
Product Description
Mechanism Of Action
palivizumab biobetter - Drug Profile
Product Description
Mechanism Of Action
palivizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
palivizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
palivizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
pertussis [strain BPZE1] vaccine - Drug Profile
Product Description
Mechanism Of Action
PF-06928316 - Drug Profile
Product Description
Mechanism Of Action
PF-07923567 - Drug Profile
Product Description
Mechanism Of Action
POLB-002 - Drug Profile
Product Description
Mechanism Of Action
Polysaccharides for Viral Infections - Drug Profile
Product Description
Mechanism Of Action
Product Candidates - Drug Profile
Product Description
Mechanism Of Action
Protein for Respiratory Syncytial Virus Infection - Drug Profile
Product Description
Mechanism Of Action
PRTX-007 - Drug Profile
Product Description
Mechanism Of Action
PSP-008 - Drug Profile
Product Description
Mechanism Of Action
ramatroban - Drug Profile
Product Description
Mechanism Of Action
RB-0026 - Drug Profile
Product Description
Mechanism Of Action
RBS-3149 - Drug Profile
Product Description
Mechanism Of Action
Recombinant Protein for Infectious Disease and Oncology - Drug Profile
Product Description
Mechanism Of Action
Recombinant Protein for RSV Infections - Drug Profile
Product Description
Mechanism Of Action
Recombinant Surfactant Associated Protein D Replacement for SARS and RSV Infections - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus (virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus (virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus (virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus (virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus (virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus (virus like particle) vaccines - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus (virus like particles) vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus [strain 98-25147-X] vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus [strain A/Maryland/001/11] vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine 2 - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine 3 - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine 3 - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine 4 - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine 5 - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine 6 - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine 7 - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccines - Drug Profile
Product Description
Mechanism Of Action
REVTx-99 - Drug Profile
Product Description
Mechanism Of Action
rilematovir - Drug Profile
Product Description
Mechanism Of Action
RLS-0071 - Drug Profile
Product Description
Mechanism Of Action
RSV - Drug Profile
Product Description
Mechanism Of Action
RSV - Drug Profile
Product Description
Mechanism Of Action
RSV - Drug Profile
Product Description
Mechanism Of Action
RSV - Drug Profile
Product Description
Mechanism Of Action
RSV Antivirals - Drug Profile
Product Description
Mechanism Of Action
RSV Artificial Intelligence Drug Discovery Program - Drug Profile
Product Description
Mechanism Of Action
RSV DFC - Drug Profile
Product Description
Mechanism Of Action
RSV Program - Drug Profile
Product Description
Mechanism Of Action
RSV Vaccine - Drug Profile
Product Description
Mechanism Of Action
RSV-276 - Drug Profile
Product Description
Mechanism Of Action
RSV-F005 - Drug Profile
Product Description
Mechanism Of Action
S-337395 - Drug Profile
Product Description
Mechanism Of Action
sisunatovir hydrochloride - Drug Profile
Product Description
Mechanism Of Action
Small Molecule 1 for Respiratory Syncytial Virus Infections - Drug Profile
Product Description
Mechanism Of Action
Small Molecule for Respiratory Syncytial Virus (RSV) Infections - Drug Profile
Product Description
Mechanism Of Action
Small Molecule for Respiratory Syncytial Virus Infections - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit RSV F Protein for Respiratory Syncytial Virus Infection - Drug Profile
Product Description
Mechanism Of Action
Small Molecules 2 for Respiratory Syncytial Virus Infections - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Respiratory Syncytial Virus (RSV) Infections - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Respiratory Syncytial Virus Infections - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit RSV F Protein for Respiratory Syncytial Virus Infection - Drug Profile
Product Description
Mechanism Of Action
SP-0125 - Drug Profile
Product Description
Mechanism Of Action
Syncytial Virus Fusion Inhibitor - Drug Profile
Product Description
Mechanism Of Action
TCB-029 - Drug Profile
Product Description
Mechanism Of Action
TD-214 - Drug Profile
Product Description
Mechanism Of Action
TE-4308 - Drug Profile
Product Description
Mechanism Of Action
TNM-001 - Drug Profile
Product Description
Mechanism Of Action
TP-0591816 - Drug Profile
Product Description
Mechanism Of Action
TRL-3D3 - Drug Profile
Product Description
Mechanism Of Action
TVB-3567 - Drug Profile
Product Description
Mechanism Of Action
TVX-004IP - Drug Profile
Product Description
Mechanism Of Action
verdinexor - Drug Profile
Product Description
Mechanism Of Action
VIS-RSV - Drug Profile
Product Description
Mechanism Of Action
VMT-3 - Drug Profile
Product Description
Mechanism Of Action
VMTX-002 - Drug Profile
Product Description
Mechanism Of Action
VN-0200 - Drug Profile
Product Description
Mechanism Of Action
VPI-251 - Drug Profile
Product Description
Mechanism Of Action
VXB-211 - Drug Profile
Product Description
Mechanism Of Action
VXX-005 - Drug Profile
Product Description
Mechanism Of Action
WLBU-2 - Drug Profile
Product Description
Mechanism Of Action
XW-001 - Drug Profile
Product Description
Mechanism Of Action
YH-009 - Drug Profile
Product Description
Mechanism Of Action
zapnometinib - Drug Profile
Product Description
Mechanism Of Action
zelpultide alfa - Drug Profile
Product Description
Mechanism Of Action
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects
Respiratory Syncytial Virus (RSV) Infections - Discontinued Products
Respiratory Syncytial Virus (RSV) Infections - Product Development Milestones
Featured News & Press Releases
Oct 23, 2022: GSK’s older adult respiratory syncytial virus (RSV) vaccine candidate shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial
Oct 18, 2022: Enanta doses first participant in Phase I RSV treatment trial
Oct 07, 2022: Ark Biopharmaceutical presents positive results in phase 3 AIRFLO study of ziresovir in RSV-infected hospitalized infants at 12th International RSV Symposium
Oct 04, 2022: Enanta commences Phase IIb trial of RSV treatment
Oct 04, 2022: Icosavax initiates phase 1 trial of IVX-A12 against RSV and hMPV in older adults
Oct 02, 2022: Enanta Pharmaceuticals announces new preclinical data for its respiratory virology programs to be presented at the 12th International RSV Symposium
Sep 29, 2022: Enanta Pharmaceuticals presents preclinical data for its respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) programs at the 12th International RSV Symposium
Sep 16, 2022: Beyfortus (nirsevimab) recommended for approval in the EU by CHMP for the prevention of RSV lower respiratory tract disease in infants
Aug 26, 2022: Pfizer reports positive Phase III data for bivalent RSV vaccine in adults
Aug 12, 2022: NIHR and Sanofi announce first patient enrolled in large European clinical study to investigate protection against RSV, the leading cause of infant hospitalisation worldwide
Jul 22, 2022: Blue Lake enrols first subject in Phase I RSV vaccine trial
Jun 28, 2022: Icosavax announces positive topline interim phase 1/1b results for VLP vaccine candidate IVX-121 against RSV
Jun 28, 2022: Bavarian Nordic announces grant of PRIME eligibility from the European Medicines Agency for its RSV vaccine candidate for the prevention of respiratory syncytial virus in older adults
Jun 24, 2022: Oral antiviral drug effective against respiratory syncytial virus (RSV) identified by biomedical sciences researchers
Jun 13, 2022: GSK reports positive Phase III data for RSV vaccine in elderly
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact the Publisher
Disclaimer

List of Tables

Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, 2022
Respiratory Syncytial Virus (RSV) Infections - Discontinued Products, 2022

List of Figures

Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Abhelix LLC
Abivax SA
ADMA Biologics Inc
Advac LLC
Advagene Biopharma Co Ltd
AIM Vaccine Co Ltd
Airway Therapeutics Inc
AlloVir Inc
Anima Biotech Inc
Aposense Ltd
Aridis Pharmaceuticals Inc
Artificial Cell Technologies Inc
AstraZeneca Plc
Atea Pharmaceuticals Inc
Atriva Therapeutics GmbH
Auro Vaccines LLC
AVM Biotechnology LLC
Bavarian Nordic AS
Beijing Advaccine Biotechnology Company Ltd
BioComo Inc
Biological E Ltd
Blue Lake Biotechnology Inc
BlueWillow Biologics Inc
BravoVax Co Ltd
Calder Biosciences Inc
Celestial Therapeutics Inc
Changchun Bcht Biotechnology Co Ltd
Chengdu Aoda Biotechnology Co Ltd
Chongqing Zhifei Biological Products Co Ltd
Cidara Therapeutics Inc
Clover Biopharmaceuticals Ltd
Codagenix Inc
ConserV Bioscience Ltd
Curevac NV
CyanVac LLC
Daiichi Sankyo Co Ltd
Enanta Pharmaceuticals Inc
Enyo Pharma SA
Esperovax Inc
Eucure (Beijing) Biopharma Co Ltd
Exopharm Ltd
F. Hoffmann-La Roche Ltd
Gilead Sciences Inc
GSK plc
HanaVax Inc
Heartland Vaccines LLC
iBio Inc
Icosavax Inc
IDBiologics Inc
ILiAD Biotechnologies LLC
Immunwork Inc
Imophoron Ltd
IMV Inc
Inhalon Biopharma Inc
Inovio Pharmaceuticals Inc
Intravacc BV
Johnson & Johnson
KARE Biosciences Inc
Karyopharm Therapeutics Inc
Kidswell Bio Corp
Mapp Biopharmaceutical Inc
Meissa Vaccines Inc
Merck & Co Inc
MicroQuin Ltd
Moderna Inc
Navigen Inc
NeuClone Pty Ltd
Neuracle Science Co Ltd
Novavax Inc
Oita University Institute of Advanced Medicine Inc
Pfizer Inc
Pinetree Therapeutics Inc
Pneumagen Ltd
Poolbeg Pharma Plc
Prime Vector Technologies GmbH
Primmune Therapeutics Inc
Prosit Sole Biotechnology (Beijing) Co Ltd
ReAlta Life Sciences Inc
Revelation Biosciences Inc
Riboscience LLC
Romark Laboratories LC
Ruiyang (Suzhou) Biotechnology Co Ltd
Sagimet Biosciences Inc
Sanofi.
Sciwind Biosciences Co Ltd
Shandong Danhong Pharmaceutical Co Ltd
Shanghai Ark Biopharmaceutical Co Ltd
Shionogi & Co Ltd
Sigmovir Biosystems Inc
Signia Therapeutics
SK Bioscience Ltd
Taisho Pharmaceutical Holdings Co Ltd
TechnoVax Inc
Trimunocor Ltd
TrippBio Inc
Uvax Bio LLC
Vault Pharma Inc
Vaxart Inc
Vaxxel SAS
Vicebio Ltd
Vir Biotechnology Inc
Viramatix Sdn Bhd
Viravaxx AG
Virometix AG
Visterra Inc
VLP Biotech Inc
X4 Pharmaceuticals Inc
XBiotech Inc
Zhuhai Trinomab Biotechnology Co Ltd

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€2454EUR$2,500USD£2,051GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€4908EUR$5,000USD£4,103GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€7362EUR$7,500USD£6,154GBP

Report Highlights

Scope

Reasons to Buy

Table of Contents

Companies Mentioned (Partial List)

Related Topics

Related Reports

Respiratory Syncytial Virus (RSV) Infections Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update

Influenza A Infections - Pipeline Insight, 2024

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Insight, 2024

Anti-infectives Market by Product, Pathogen, Mechanism Of Action, Route Of Administration, End User - Global Forecast 2025-2030

Anti-infective Agents Market - Global Industry Size, Share, Trends, Opportunity, & Forecast 2018-2028